Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-10-2010 | Original Article

Biodistribution and radiation dosimetry of ¹¹C-labelled docetaxel in cancer patients

Authors: Astrid A. M. van der Veldt, N. Harry Hendrikse, Egbert F. Smit, Martien P. J. Mooijer, Anneloes Y. Rijnders, Winald R. Gerritsen, Jacobus J. M. van der Hoeven, Albert D. Windhorst, Adriaan A. Lammertsma, Mark Lubberink

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2010

Abstract

Purpose

Docetaxel is an important chemotherapeutic agent used for the treatment of several cancer types. As radiolabelled anticancer agents provide a potential means for personalized treatment planning, docetaxel was labelled with the positron emitter ¹¹C. Non-invasive measurements of [¹¹C]docetaxel uptake in organs and tumours may provide additional information on pharmacokinetics and pharmacodynamics of the drug docetaxel. The purpose of the present study was to determine the biodistribution and radiation absorbed dose of [¹¹C]docetaxel in humans.

Methods

Biodistribution of [¹¹C]docetaxel was measured in seven patients (five men and two women) with solid tumours using PET/CT. Venous blood samples were collected to measure activity in blood and plasma. Regions of interest (ROI) for various source organs were defined on PET (high [¹¹C]docetaxel uptake) or CT (low [¹¹C]docetaxel uptake). ROI data were used to generate time-activity curves and to calculate percentage injected dose and residence times. Radiation absorbed doses were calculated according to the MIRD method using OLINDA/EXM 1.0 software.

Results

Gall bladder and liver demonstrated high [¹¹C]docetaxel uptake, whilst uptake in brain and normal lung was low. The percentage injected dose at 1 h in the liver was 47 ± 9%. [¹¹C]docetaxel was rapidly cleared from plasma and no radiolabelled metabolites were detected. [¹¹C]docetaxel uptake in tumours was moderate and highly variable between tumours.

Conclusion

The effective dose of [¹¹C]docetaxel was 4.7 µSv/MBq. As uptake in normal lung is low, [¹¹C]docetaxel may be a promising tracer for tumours in the thoracic region.

Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421–3.CrossRefPubMed

Van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des 2008;14:2914–31.CrossRefPubMed

Van der Veldt AA, Lammertsma AA, Hendrikse NH. [11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics. Clin Cancer Res 2007;13:7522–3.CrossRefPubMed

Van Tilburg EW, Franssen EJ, Van der Hoeven JJ, Van der Meij M, Elshove D, Lammertsma AA, et al. Radiosynthesis of [11C]docetaxel. J Labelled Comp Radiopharm 2004;47:763–77.CrossRef

Van Tilburg EW, Mooijer MP, Brinkhorst J, Van der Meij M, Windhorst AD. Improved and semi-automated GMP-compliant radiosynthesis of [11C]docetaxel. Appl Radiat Isot 2008;66:1414–8.CrossRefPubMed

Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229–39.CrossRefPubMed

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.CrossRefPubMed

Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007;48:471–80.PubMed

Hoekstra CJ, Hoekstra OS, Lammertsma AA. On the use of the injection catheter for venous blood sampling in quantitative FDG PET studies. Eur J Nucl Med 2000;27:1579.CrossRefPubMed

10.

International Commission on Radiological Protection. Report of the Task Group on Reference Man. ICRP Publication 23. New York: Pergamon; 1975.

11.

Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. Oak Ridge: Oak Ridge National Laboratory; 1987.

12.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.PubMed

13.

International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication 30. New York: Pergamon; 1979.

14.

International Commission on Radiological Protection. The 1990 Recommendations. Ann ICRP 1991;21:1–3.

15.

International Commission on Radiological Protection. The 2007 Recommendations. Ann ICRP 2007;37:2–4.

16.

Hirvonen J, Roivainen A, Virta J, Helin S, Någren K, Rinne JO. Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imaging 2010;37:606–12.CrossRefPubMed

17.

International Commission on Radiological Protection. Radiological protection in biomedical research. ICRP Publication 62. New York: Pergamon; 1991.

18.

FDA. Food and Drug Administration Code of Federal Regulations. 21 CFR 361–1. 1991.

19.

Rosing H, Lustig V, Van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Schellens JH, et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000;45:213–8.CrossRefPubMed

20.

Liu N, Li M, Li X, Meng X, Yang G, Zhao S, et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med 2009;50:303–8.CrossRefPubMed

21.

Slifstein M, Hwang DR, Martinez D, Ekelund J, Huang Y, Hackett E, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med 2006;47:313–9.PubMed

22.

Kalen JD, Hirsch JI, Kurdziel KA, Eckelman WC, Kiesewetter DO. Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]paclitaxel (FPAC). Appl Radiat Isot 2007;65:696–700.CrossRefPubMed

23.

Kiesewetter DO, Jagoda EM, Kao CH, Ma Y, Ravasi L, Shimoji K, et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl Med Biol 2003;30:11–24.CrossRefPubMed

24.

Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Agarwal R, Barrett D, et al. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl Med Biol 2007;34:823–31.CrossRefPubMed

25.

Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950–8.PubMed

26.

Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159–64.PubMed

27.

Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735–8.CrossRefPubMed

28.

Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18:v3–8.CrossRefPubMed

29.

Sanson M, Napolitano M, Yaya R, Keime-Guibert F, Broët P, Hoang-Xuan K, et al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 2000;50:245–9.CrossRefPubMed

30.

Bart J, Groen HJ, Van der Graaf WT, Hollema H, Hendrikse NH, Vaalburg W, et al. An oncological view on the blood-testis barrier. Lancet Oncol 2002;3:357–63.CrossRefPubMed

Title: Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients
Authors: Astrid A. M. van der Veldt
N. Harry Hendrikse
Egbert F. Smit
Martien P. J. Mooijer
Anneloes Y. Rijnders
Winald R. Gerritsen
Jacobus J. M. van der Hoeven
Albert D. Windhorst
Adriaan A. Lammertsma
Mark Lubberink
Publication date: 01-10-2010
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1489-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Biodistribution and radiation dosimetry of ¹¹C-labelled docetaxel in cancer patients

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2010

New SPECT technology: potential and challenges

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

FDG-PET/CT in infections: the imaging method of choice?